A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)-Reference-Cited by-同舟云学术

A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe–Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)

Published:2011-07 Issue:11 Volume:47 Page:1653-1659
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Belvedere Ornella,Follador Alessandro,Rossetto Ciro,Merlo Valentina,Defferrari Carlotta,Sibau Angela M.,Aita Marianna,Dal Bello Maria G.,Meduri Stefano,Gaiardo Marica,Fasola Gianpiero,Grossi Francesco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer;Azzoli;J Clin Oncol,2009

2. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel;Rixe;Biochem Pharmacol,1996

3. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate use experience;Faivre;Ann Oncol,1999

4. Cellular and molecular pharmacology of oxaliplatin;Raymond;Mol Cancer Ther,2002

5. Oxaliplatin (l-OHP) association with paclitaxel (PTX) or docetaxel (DTX in NSCLC cell lines: Schedule dependent activity based on p53/microtubule associate protein 4 (MAP4) interaction;Antonini-Cappellini;Ann Oncol,2002

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials;Translational Lung Cancer Research;2021-05

2. Lung Adenocarcinoma;Pulmonary Adenocarcinoma: Approaches to Treatment;2019

3. Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer;Scientific Reports;2018-06-26

4. Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC who Failed First-Line Treatment;Clinical Therapeutics;2014-12

5. Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer;Thoracic Cancer;2014-10-23